KalVista Presented Additional Analyses Of Efficacy And Safety Of Sebetralstat From Phase 2 And Phase 3 Double-blind, Placebo-controlled Crossover Clinical Trials As Well As Interim Data From KONFIDENT-S, A Phase 3 Open-label Extension Trial
Portfolio Pulse from Nabaparna Bhattacharya
KalVista Pharmaceuticals presented new analyses on the efficacy and safety of Sebetralstat, an investigational treatment for hereditary angioedema, at the Bradykinin Symposium 2024. The data includes results from Phase 2 and Phase 3 trials, as well as interim data from an open-label extension trial.
September 06, 2024 | 10:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KalVista Pharmaceuticals presented positive data on Sebetralstat, a treatment for hereditary angioedema, at a major symposium. This could enhance investor confidence in the drug's potential market success.
The presentation of positive trial data at a significant symposium suggests that Sebetralstat is progressing well in its development. This can boost investor confidence and potentially lead to a positive short-term impact on KalVista's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90